Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses whether including drugs' list prices in consumer advertising will help drive down prices for patients.
Transcript:
Would disclosing drugs' list prices in ads help drive down prices for patients?
To be honest, I don’t think disclosing list prices is really going to have the difference that we need to see in the current marketplace, in the current crisis that we’re facing regarding drug pricing.
I think it’s useful to have the list pricing there, but will that really change essentially where the abuse is really happening? We believe it has to lie in changing the patent system, in changing how we hand out 20-year monopoly periods to companies. Until you do that, you really aren’t going to see marked changes, and companies will find other ways to strategically cover up the list pricing in other ways.
I don’t think that’s a measure that really helps. I think that’s really a deflection, if anything, [rather than] going to the source of the problem.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.